CLINICA OMEGA VISION, with the aim of continuing to improve the quality of the eye exam service, becomes the first health center in Lanzarote to have an advanced OCT Angiography system for the diagnosis of retina, glaucoma and anterior segment.
For clinical practice, this platform allows, among its different diagnoses, the early detection of Macular Degeneration (AMD) and Glaucoma, both diseases are the main causes of blindness in the world.

Spectralis represents a great advance in understanding pathologies associated with the macula and the optic nerve. In addition, it is 100% oriented to early detection. This new harmless technology, since without the need to inject a contrast into the patient, makes a difference with other fundus examinations since OCT angiography offers more precise images to diagnose the various pathologies of the retina, glaucoma and anterior segment.
It is estimated that diabetes will increase continuously in the coming years and the visualization of microaneurysms, considered the first detectable pathological sign in patients with diabetic retinopathy, could play a key role in the detection of this pathology.
The installation and commissioning of this new technology at Clínica Omega Visión, in addition to offering better tools for specialists, represents a great improvement for patients residing in Lanzarote as they can be treated with advanced and safe technology without having to leave the island.
The SPECTRALIS® platform has been selected by the National Aeronautics and Space Administration NASA, within the program The Vision Impairment and Intracranial Pressure (VIIP), as a reference examination for the retina review of astronauts who carry out their activity in the International Space Station.
Find out at:
Clínica Omega Visión
- Calle Dr. Gómez Ulla, 70, 35500 Arrecife, Lanzarote
- Monday to Friday from 9:00 a.m. to 8:00 p.m.
- Telephone: 928.81.06.41
- www.clinicaomegalanzarote.com